Immunoinformatics Identifies a Lactoferrin Binding Protein A Peptide as a Promising Vaccine With a Global Protective
Gehad M Yassin1, Magdy A Amin2, Ahmed S Attia2
1Quality Control Sector, Arab Drug Company, Cairo.
Background:
Moraxella catarrhalis is an established pathogen that is causing substantial infections to both children and adults. However, so far there is no effective vaccine to halt the spread of these infections.
Methods:
Immunoinformatics tools were used to predict M. catarrhalis epitopes that could offer immunoprotection among major proportions of human populations worldwide. Mice were immunized with the best 3 peptides and then challenged with M. catarrhalis in the pulmonary clearance model. Finally, antibodies against these epitopes were detected in humans.
Results:
Immunoinformatics analyses identified 44 epitopes that are predicted to be good major histocompatibility complex class II binders and at the same time show high population coverage worldwide. After intraperitoneal immunization of mice with the best 3 peptides, peptide A, derived from lactoferrin-binding protein A, showed superior activity in immunogenicity and in clearing M. catarrhalis from mouse lungs. Higher clearance was obtained by combining intraperitoneal and intranasal immunization. In the serum samples from children with otitis media infected with M. catarrhalis, antibody levels against peptide A were significantly lower than in samples from children without otitis media.
Conclusions:
Peptide A is the first promising peptide-based vaccine against M. catarrhalis Immunoinformatics predicts that it should have a global protection around the world.
Insights
A novel peptide A vaccine shows promise against Moraxella catarrhalis infections. This peptide, identified using immunoinformatics, demonstrated effective clearance in mice and potential global protection.
Area of Science:
- Microbiology
- Immunology
- Vaccine Development
Background:
- Moraxella catarrhalis is a significant pathogen causing infections in children and adults.
- Current limitations exist in preventing M. catarrhalis infections due to the lack of an effective vaccine.
Purpose of the Study:
- To identify potential vaccine candidates for Moraxella catarrhalis using immunoinformatics.
- To evaluate the immunogenicity and efficacy of predicted epitopes in preclinical models.
Main Methods:
- Immunoinformatics tools were employed to predict M. catarrhalis epitopes with high population coverage.
- Mice were immunized with top-ranked peptides, including peptide A derived from lactoferrin-binding protein A.
- Efficacy was assessed through pulmonary clearance models and antibody detection in human serum samples.
Main Results:
- Forty-four potential epitopes were identified, with high predicted binding to MHC class II and broad population coverage.
- Peptide A demonstrated superior immunogenicity and efficacy in clearing M. catarrhalis from mouse lungs, enhanced by combined immunization routes.
- Lower antibody levels against peptide A were observed in children with M. catarrhalis-infected otitis media.
Conclusions:
- Peptide A represents a promising first peptide-based vaccine candidate against Moraxella catarrhalis.
- Immunoinformatics predictions suggest potential global protection against M. catarrhalis infections with peptide A.
